Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Rutgers the State University

Neither a doctor nor a teaching hospital

Research payments

$20,324,047

2,895 payments

Through program year 2025, Rutgers the State University is reported as receiving $20,324,047 in research payments, across 2,895 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,902,552 1,116
2024 Research $3,352,530 501
2023 Research $2,929,337 361
2022 Research $2,245,091 227
2021 Research $1,514,858 223
2020 Research $3,235,437 290
2019 Research $2,144,244 177

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $5,293,438 914 payments
  2. Janssen Research & Development, LLC $3,286,908 322 payments
  3. Pfizer Inc. $1,949,201 123 payments
  4. Edwards Lifesciences Corporation $1,389,002 99 payments
  5. AbbVie, Inc. $1,131,764 163 payments
  6. GlaxoSmithKline, LLC. $789,173 31 payments
  7. Genentech, Inc. $622,831 53 payments
  8. EMD Serono, Inc. $396,704 129 payments
  9. Stemline Therapeutics Inc. $378,777 328 payments
  10. Merck Sharp & Dohme Corporation $368,900 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20+ B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy $1,660,338 34 payments
  2. A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma $1,118,920 488 payments
  3. Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma $832,216 51 payments
  4. Full Modifying the Risk and Outcome of Heart Failure in Patients With Rheumatoid Arthritis Is Tofacitinib A Better Option Compared to Other Dmards Phase I $782,557 1 payment
  5. A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma $645,464 43 payments
  6. Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer $621,220 164 payments
  7. Study name not reported $585,200 5 payments
  8. Validity of Claimsbased Definitions for Rheumatoid Arthritis Selected Cancers and Infectious Diseases in Japan $520,886 22 payments
  9. Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma $491,244 164 payments
  10. THE ENCIRCLE Trial (#2018-19) $398,345 18 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $32,368 2 payments
  2. Non-patient care $32,216 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record